NanoViricides, Inc. (NYSE American: NNVC) has announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company's proposed clinical trial has received approval from the DRC Pillar Committee, with preparations now underway for ethics and regulatory submissions. NV-387 is noted as the only orally administered Ebola treatment candidate currently under consideration for clinical trials, which could provide significant advantages in resource-limited settings where infusion-based therapies are difficult to deploy.
The outbreak has expanded substantially, with 1,561 confirmed cases and 506 deaths reported in the DRC as of July 6. No approved treatment or vaccine currently exists for the Bundibugyo strain, underscoring the urgent need for effective interventions. NanoViricides believes that NV-387's broad-spectrum antiviral mechanism could offer activity against multiple ebolavirus strains. The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product shipped to the country for that study.
The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The nanoviricide technology platform is based on intellectual property licensed from TheraCour Pharma, Inc. NanoViricides holds exclusive sublicensable field licenses for several viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses.
The advancement of NV-387 for Bundibugyo Ebola represents a potential breakthrough in outbreak response, particularly given the logistical challenges of administering intravenous therapies in the DRC. The oral gummies formulation could enable broader access to treatment, reducing the burden on healthcare infrastructure. As the outbreak continues to grow, the need for effective, deployable treatments becomes increasingly critical.
For more details, the full press release is available at https://ibn.fm/LaNwF. Additional information about NanoViricides can be found at https://ibn.fm/NNVC.
